Clinical Trials Browser

Phase 2 × Disease × Plasma cell × Clear all

NCT03896737 2025-08-11

Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

Phase 2 Active not recruiting

Disease, Multiple Myeloma

NCT01190787 2024-01-23

Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone

Phase 2 Completed

Disease, Multiple Myeloma

NCT01160107 2023-06-29

RP_MPR

Phase 2 Completed

Disease, Multiple Myeloma